Your browser doesn't support javascript.
loading
Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population.
Krashias, George; Deeba, Elie; Constantinou, Astero; Hadjiagapiou, Maria; Koptides, Dana; Richter, Jan; Tryfonos, Christina; Bashiardes, Stavros; Lambrianides, Anastasia; Loizidou, Maria A; Hadjisavvas, Andreas; Panayiotidis, Mihalis I; Christodoulou, Christina.
Afiliação
  • Krashias G; Cyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
  • Deeba E; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Constantinou A; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Hadjiagapiou M; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Koptides D; Cyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
  • Richter J; Department of Neuroimmunology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Tryfonos C; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Bashiardes S; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Lambrianides A; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Loizidou MA; Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Hadjisavvas A; Cyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
  • Panayiotidis MI; Department of Neuroimmunology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Christodoulou C; Cyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
Microorganisms ; 10(1)2021 Dec 31.
Article em En | MEDLINE | ID: mdl-35056533
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has hit its second year and continues to damage lives and livelihoods across the globe. There continues to be a global effort to present serological data on SARS-CoV-2 antibodies in different individuals. As such, this study aimed to characterize the seroprevalence of SARS-CoV-2 antibodies in the Cypriot population for the first time since the pandemic started. Our results show that a majority of people infected with SARS-CoV-2 developed IgG antibodies against the virus, whether anti-NP, anti-S1RBD, or both, at least 20 days after their infection. Additionally, the percentage of people with at least one antibody against SARS-CoV-2 in the group of volunteers deemed SARS-CoV-2 negative via RT-PCR or who remain untested/undetermined (14.43%) is comparable to other reported percentages worldwide, ranging anywhere from 0.2% to 24%. We postulate that these percentages reflect the underreporting of true infections in the population, and also show the steady increase of herd immunity. Additionally, we showed a significantly marked decrease in anti-NP IgG antibodies in contrast to relatively stable levels of anti-S1RBD IgG antibodies in previously infected individuals across time.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Microorganisms Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Chipre País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Microorganisms Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Chipre País de publicação: Suíça